Publications by authors named "Christopher D Scrase"

Claim this Profile
S
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Christopher D Scrase

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Ruth E Langley, Duncan C Gilbert, Trinh Duong, Noel W Clarke, Matthew Nankivell, Christopher D Scrase

Lancet· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
David Dearnaley, Clare L Griffin, Rebecca Lewis, Philip Mayles, Helen Mayles, Christopher D Scrase

Int J Radiat Oncol Biol Phys· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, Cyril Fisher, Isabel Syndikus, Christopher D Scrase

Eur Urol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Ruth E Langley, Howard G Kynaston, Abdulla A Alhasso, Trinh Duong, Edgar M Paez, Christopher D Scrase

Eur Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
David P Dearnaley, Gordana Jovic, Isabel Syndikus, Vincent Khoo, Richard A Cowan, Christopher D Scrase

Lancet Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score--report from a single U.K. institution.
Charlotte J Ingle, Kent Yip, Valerie Caskie, Catherine Dyson, Amanda Ford, Christopher D Scrase

Head Neck Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
David P Dearnaley, Matthew R Sydes, John D Graham, Edwin G Aird, David Bottomley, Christopher D Scrase

Lancet Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).
David P Dearnaley, Matthew R Sydes, Ruth E Langley, John D Graham, Robert A Huddart, Christopher D Scrase

Radiother Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis